UNSPSC 51283955: Sulfathiazole sodium

This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H8N3O2S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PV16N742VM, chemically known as sulfanilamide, n(sup 1)-2-thiazolyl-, n(sup 1)-sodium deriv. but more generally known as sulfathiazole sodium, which bears US NIH Compound Identifier 67415. Most nations, for tariff and trade purposes, schedule sulfathiazole sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFATHIAZOLE SODIUM remains US FDA's Preferred Term for this commodity.

SMILES: C1CC(CCC1N)S(=O)(=O)[N-]C2NCCS2.[NA+].

UNSPSC 51283955 Sulfathiazole sodium is a Commodity code for a specific pharmaceutical active ingredient, but the recent state and local opportunities tagged under it do not reflect sulfathiazole procurement. Instead, the code shows activity for broader pharmaceutical warehouse supply and emergency medical countermeasures — including antibiotic tablets, naloxone, and drug deactivation systems. State and local health departments and county health authorities are the primary issuing bodies, using cooperative purchasing vehicles (such as MMCAP Infuse) and traditional competitive bidding to source these products for public health stockpiles, emergency preparedness, and community health initiatives. The scope reflects purchasing of off-patent pharmaceuticals and public health commodities in bulk quantities, often with multi-year contract terms and quarterly or on-call delivery schedules.

Recent opportunities include the Illinois Department of Public Health's award to Chartwell Rx LLC through the MMCAP Infuse consortium (August 28, 2026) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets totaling $2,999,999.11 over three years, and Seminole County, Florida's IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually (posted June 30, 2026, due July 26). Activity appears concentrated in Florida and Illinois, with awards and solicitations spanning state health departments and county community health operations. The mismatch between the code's specific name and the actual purchasing activity suggests that sulfathiazole itself may see minimal state and local solicitation, or that these jurisdictions are tagging related pharmaceutical commodity buys under a broader code. Vendors pursuing this code should expect cooperative purchasing and traditional competitive bid opportunities from public health departments and emergency management offices, with emphasis on compliance, delivery logistics, and pricing competitiveness.